News

Afrezza is a novel, ultra rapid acting mealtime insulin therapy being developed by MannKind for the treatment of adult patients with type 1 and type 2 diabetes for

Luigi Stasi, director of medicinal chemistry department at Rottapharm, said: “We are delighted to start an FTE-based collaboration with Selvita. We are keen to take advantage of Selvita’s

Trial By Fire Solutions said that SimpleCTMS was developed as Software as a Service (SaaS) and it provides biotechnology, pharmaceutical, and medical device companies a flexible, intuitive, comprehensive

Net earnings and diluted earnings per share for the second quarter of 2010 were $3.4bn and $1.23, respectively. J&J said that excluding the special item, net earnings for

Eisai said that the oral suspension formulation was developed to provide a new treatment option for children four years and older and adults who have trouble swallowing tablets.

Bionas claimed that the technology allows for the analysis of cellular behavior in real-time without the use of any dyes or antibodies, thus avoiding the result being biased

NIAID used a Selectivity Index (SI) to determine the effectiveness of a compound. The SI measures EC50 (50% virus-inhibitory (effective) concentration and EC90 (90%) cell inhibitory (cytotoxic) concentration

In a trial, Civanex showed reduction in the Western Ontario and McMaster Universities Arthritis Index (WOMAC) Pain scale, the WOMAC Physical Function Subscale and a Patient Global Evaluation

DermSafe is a patented hand sanitizer, formulated with 4% chlorhexidine gluconate, an active ingredient used internationally as a pre-surgical scrub and in periodontal products. Skinvisible and RHEI claimed